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Spiked human plasmaAbstract In this stability-indicating, reversed-phase high-performance liquid chromatographic
method for nicardipine (NIC), forced degradation has been employed and the formed degradants
were separated on a C18 (150 mm · 3.9 mm, 5 lm) analytical column using a mobile phase con-
sisted of 70% methanol: acetic acid containing 0.01 M triethylamine with pH 4. The ﬂow rate
was 1.0 mL/min and the photodiode array detection wavelength was 353 nm. Forced degradation
of the drug was carried out under acidic, basic, photolytic, and oxidative stress conditions. Chro-
matographic peak purity data indicated no co-eluting peaks with the main peaks. This method
resulted in the detection of seven degradation products. Among these, two major degradation prod-
ucts from basic hydrolysis, one from oxidation by H2O2 and four from photolytic stress were iden-
tiﬁed by mass spectral data. A good linear response was achieved over the range of 0.5–40 lg/mL
with a limit of detection (LOD) of 0.011 lg/mL and limit of quantiﬁcation (LOQ) of 0.036 lg/mL.
The suggested method was successfully applied for the analysis of NIC in its commercial capsules,
with mean% recovery value of 100.11 ± 2.26%. The method was extended to the in vitro determi-
nation on NIC in spiked human plasma samples with mean% recovery of 99.04 ± 5.67%. The sug-
gested method was utilized to investigate the kinetics of photolytic induced degradation.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Calcium channel blockers (CCBs) are established in therapies
for the treatment of high blood pressure, angina, and certain
heart rhythm abnormalities. They lower blood pressure by a
direct and selective relaxing effect on the smooth muscle cells,
especially those of resistance vessels (Michalewicz and
Messerli, 1997). This helps to maintain blood ﬂow to the heartd spiked
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2 S.M. Al-Ghannam, A.M. Al-Olayanand reduce the frequency and severity of angina attacks. CCBs
are used in monotherapy as well as combined with angiotensin-
converting enzyme (ACE) inhibitors or b-blockers (Domenic,
2001). Nicardipine (NIC) is one of the CCBs. NIC is a substi-
tuted 1,4 dihydropyridine derivative and chemically designed
as [2-benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitro-
phenyl)-1,4-dihydropyridine-3,5-dicarboxylate] Fig. 1. Being a
dihydropyridine derivative, NIC is widely used in the treatment
of hypertension and angina pectoris (Graham et al., 1985).
It is known that calcium antagonists from the group of 1,4-
dihydropyridine derivatives are liable to photochemical decom-
position to give degradation products that have no pharmacolog-
ical activity (Brogden and Mc Tavish, 1995; Zhang et al., 1998;
Faust, 1993). The degradation is usually brought about by any
of the following methods: oxidation, hydrolysis and photo decay.
Several papers can be cited in the literature demonstrating
the occurrence of various decomposition products based on
HPLC/MS (Chen et al., 2007; Marinkovic et al., 2003;
Barandaa et al., 2006), GC/MS (Mielcarek et al., 2000) and
spectrophotometric (Ragno et al., 2002; Ragno et al., 2006)
methods. Drugs that possess certain labile functional groups
are prone to decomposition particularly when formulated in
liquid preparations. The assay of these formulations can be
carried out by a suitable stability indicating method, e.g.
HPLC which is by far the method that is most widely used
today as a stability indicating method. Stability-indicating
methods are required for the assay of drug formulations where
the intact drug and its degrading products coexist together.
Stress testing of the drug was also conducted, according to
the ICH Guideline to support the suitability of the method.
The system suitability was used to verify if the resolution
and injection repeatability of the chromatographic system were
adequate (ICH-Harmonised Tripartite Guideline, 2003).480.24
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Figure 1 Positive ion electro spray MS of nicardipine (10 lg/mL)
methanolic solution infused at 10 lL/min. MS conditions: 30 V for
cone voltage, 3300 V for capillary voltage, 1.5 V for extraction
voltage and a typical chromatogram on NIC (10 lg/mL).
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kinetics was performed in order to provide evidence about
the quality of the drug varies with time under the inﬂuence
of photolytic conditions.
In the present work, a RP-HPLC method with UV–MS
detection was utilized to separate the drug from its degrada-
tion products generated during the stress test with retention
time less than 10 min and to characterize the major degra-
dants. This method could be applied for the quantitative deter-
mination of the studied drug in capsules, as well as in human
plasma.2. Experimental
2.1. Materials and chemicals
Nicardipine HCl (99.84% w/w, Lot No. 16H0190), was pur-
chased from Sigma Chemical Company (St. Louis, MO,Figure 2 HPLC–UV chromatogram of nicardipine (10 lm g/
mL) in methanolic solution incubation with (a) hydrochloric acid
1 M (b) sodium hydroxide 0.4 M (c) hydrogen peroxide 5% (d)
exposed to UV radiation (irradiation time: 210 min), injection
volume 10 lL, Flow rate 0.250 mL/min., Detection at 353 nm.
ating HPLC method for the determination of nicardipine in capsules and spiked
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Table 1 Effect of concentration of sodium hydroxide on the kinetic parameters of nicardipine (10 lg/mL) at room temperature.
Conc. of NaOH (M) Slope K (min1) logK t1/2 (min)
0.1 0.00015 0.000345 3.46161 2006.079
0.2 0.00027 0.000622 3.20634 1114.488
0.3 0.00034 0.000783 3.10623 885.0349
0.4 0.00044 0.001013 2.99425 683.8906
0.5 0.0009 0.002073 2.68346 334.3465
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Figure 3 Effect of concentration of sodium hydroxide on the
rate of degradation of Nicardipine HCl (10 lg/mL) at room
temperature.
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Figure 4 Three-dimensional plot representing log(a/a–x)-degra-
dation time relationship for nicardipine HCl (10 lg/mL) at
different temperatures in 0.2 M NaOH.
Stability-indicating HPLC method for the determination of nicardipine in capsules and spiked human plasma 3USA). 0.5 M Sodium hydroxide (BDH, UK), 1 M Hydrochlo-
ric acid (Fluka Darmstadl, Switzerland), 5% Hydrogen perox-
ide (Riede-de Haen, Germany), 99.8% Methanol (BDH, UK),
0.01 M Triethyl amine (TEA) (Riede-de Haen, Germany) werePlease cite this article in press as: Al-Ghannam, S.M., Al-Olayan, A.M. Stability-indic
human plasma. Identiﬁcation of degradation products using HPLC/MS. Arabian Joalso used. The nicardipine capsules (Pelcard capsule) con-
tained 50 mg of nicardipine per capsule (Global Napi Pharma-
ceuticals, Egypt) were purchased from commercial pharmacy.
Pooled blank plasma was obtained from King Fahd Military
Medical Complex (Dhahran, Saudi Arabia).
2.2. Instrumentation
2.2.1. Mass spectrometry
Identiﬁcation of intermediate products was performed by LC/
MS. LC/MS experiments were carried out using a Waters
Micromass ZQ Detector (Waters, Milford, USA) Quadrupole
mass analyzer (mass range 2–2000 amu) equipped with electro-
spray ionization (ESI) interface in positive mode. The needle
voltage was approximately 3500 v and the cone voltage was
held at approximately 60 v. MS data acquisition and analysis
were performed using MassLynx 4.0 software Micromass
version 3.5.
2.2.2. Chromatographic conditions
Separations were carried out using a Waters 2695 Separation
Module (Waters, Milford, USA) system consisting of a vac-
uum degassing module Rheodyne Model 7725 injector
equipped with a 20 lL loop, a quaternary pump, column hea-
ter and variable wavelength detector. Data acquisition was
performed using the MassLynx 4.0 software Micromass
version 3.5. The column was Waters Symmetry C18
150 mm · 3.9 mm, 5 lm particles size. The column tempera-
ture was maintained at 25 C and the ﬂow rate was
1.0 mL min1. The detector wavelength was set at 353 nm.
The mobile phase consisted of 70% methanol: acetic acid con-
taining 0.01 M triethylamine with pH 4 (Al-Ghannam and Al-
Olyan, 2009).
2.2.3. Spectrophotometry
The spectrophotometric analysis was performed on double
beam UV/Visible spectrophotometer V-350 (Jasco, Japan)
with matched 1-cm quartz cells.
2.3. Preparation of samples
2.3.1. Preparation of standard solutions and calibration graphs
A stock solution containing 1 mg/mL of NIC was prepared in
methanol. NIC stock solution was further diluted with the
same solvent and then with the mobile phase as appropriate
to obtain the working standard solutions ranging between
0.5 and 40 lg/mL. The peak area ratio was plotted versus
the concentration of the drug (lg/mL) to get the calibration
graph. Alternatively, the corresponding regression equationating HPLC method for the determination of nicardipine in capsules and spiked
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.044
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Table 2 Effect of temperature on the kinetic parameters of nicardipine (10 lg/mL) at different concentration of sodium hydroxide.
Conc. of NaOH Temperature C Slope K (min1) logK t1/2 (min) Ea (J/mol K)
0.1 M 50 0.0013 0.00299 2.52 231 29.12
60 0.0018 0.00415 2.38 167 95.16
70 0.0049 0.01128 1.95 61 41.52
80 0.0074 0.01704 1.77 41 Mean 55.27
0.2 M 50 0.0022 0.00507 2.30 137 53.50
60 0.004 0.00921 2.04 75 95.26
70 0.0109 0.02510 1.60 28 48.26
80 0.0176 0.04053 1.39 17 Mean 65.67
0.3 M 50 0.0033 0.00760 2.12 91 53.50
60 0.006 0.01382 1.86 50 90.80
70 0.0156 0.03593 1.44 19 49.89
80 0.0256 0.05896 1.23 12 Mean 64.73
0.4 M 50 0.0045 0.01036 1.98 67 63.99
60 0.0092 0.02119 1.67 33 54.35
70 0.0163 0.03754 1.43 18 78.12
80 0.0354 0.08153 1.09 9 Mean 65.49
0.5 M 50 0.0055 0.01267 1.90 55 66.78
60 0.0116 0.02671 1.57 26 77.42
70 0.0262 0.06034 1.22 11 40.84
80 0.0393 0.09051 1.04 8 Mean 61.68
4 S.M. Al-Ghannam, A.M. Al-Olayanwas derived. The stock solutions were found to be stable for at
least two weeks when kept at 4 C.
2.3.2. Preparation of capsules solutions
Ten capsules from NIC formulation (50 mg/capsule) were
weighed and emptied then mixed well. Appropriate amount
of the powdered capsules equivalent to 50 mg of the drug
was transferred into 50 mL volumetric ﬂask sonicated well
with 80 mL methanol for 20 min. Then the solution was com-
pleted to the volume with the same solvent to give a stock solu-
tion of 1 mg/mL of NIC. This solution was ﬁltered through
millipore ﬁlter (0.45 lm pore size) and aliquots of this solution
were diluted with the mobile phase as appropriate. The nomi-
nal contents of the capsules were calculated using either the
calibration graph or the corresponding regression equation.
2.3.3. Assay of NIC in human plasma
1.5 mL aliquots of plasma were transferred into a set of centri-
fugation tubes. Aliquots from the drug stock solution were
added so that the ﬁnal concentration is in the range 5–40 lg/
mL. The solution was mixed thoroughly using a vortex mixer.
0.5 mL of 0.5 M borate buffer (pH 9.0) and 5 mL of n-hexane/
butanol (12:1 v/v) were added to each tube and gently mixedTable 3 Effect of temperature on the kinetic parameters of
nicardipine (10 lg/mL) degraded with H2O2 5%.
Temperature C Slope K (min1) t1/2 (min) Ea (J/mol K)
25 0.0092 0.02119 33 21.21
30 0.0122 0.02810 25 98.16
40 0.0423 0.09742 7 102.5
50 0.143 0.32933 2 Mean 73.96
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phase was then transferred to a set of small beakers and evap-
orated under a stream of nitrogen. The residue was dissolved
in 10 mL methanol. Aliquots of 30 lL were injected (triplicate)
and eluted with mobile phase under the reported chromato-
graphic conditions. A blank sample using plasma without
the drug was measured simultaneously. The peak area ratio
was plotted versus the concentration of the drug in lg/mL.
The corresponding regression equation was derived.2.4. Degradation conditions
2.4.1. Acid degradation
The effect of strong acid was studied in 10 mL volumetric ﬂask
by treating 10 lg/mL solution of NIC with 1 MHCl. This solu-
tion was heated at 60 C for 1 h. Samples were withdraw (1 mL)
every 10 min. and then neutralized with the corresponding0.0
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Figure 5 Change in the absorption spectrum of nicardipine
solution (10 lg/mL) in methanol after UV irradiation (0–210 min).
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Figure 6 Positive ion electrospray MS of nicardipine (10 lg/mL) methanolic solution incubation with sodium hydroxide (0.4 M) for
60 min at 60 C, MS conditions: 30 V for cone voltage, 3300 V for capillary voltage, 1.5 V for extraction voltage.
Stability-indicating HPLC method for the determination of nicardipine in capsules and spiked human plasma 5volume of 1 MNaOH and analyzed by the previously described
HPLC/MS method.
2.4.2. Base degradation
The effect of strong alkalis was studied in 10 mL volumetric
ﬂask by treating 10 lg/mL solution of nicardipine with differ-
ent concentrations of NaOH (0.1, 0.2, 0.3, 0.4 and 0.5 M). This
solution was heated at (50, 60, 70 and 80 C) for 1 h. Samples
were withdraw (1 mL) every 10 min. and then neutralized with
the corresponding volume of 1 M HCl and analyzed by the
previously described HPLC/MS method.
2.4.3. Oxidative degradation
The effect of hydrogen peroxide was studied in 10 mL volu-
metric ﬂask by treating 10 lg/mL solution of nicardipine 5%
with H2O2. This solution heated at (30, 40 and 50 C) for
5 h. Samples were withdraw (1 mL) every 1 h then neutralized
and analyzed by the previously described HPLC/MS method.
2.4.4. UV degradation
For the kinetic study of photo degradation, the experiments
were carried out at room temperature (25 ± 2 C) in a box
containing a UV light system. A 4-Watt, short/long wave
Ultraviolet lamp, two separate tubes (254 and 365 nm),Please cite this article in press as: Al-Ghannam, S.M., Al-Olayan, A.M. Stability-indic
human plasma. Identiﬁcation of degradation products using HPLC/MS. Arabian Jointensity, (lw/cm2): 760/720 at 300 (Cole Parmer, USA).
10 lg/mL Nicardipine methanolic solutions was placed in a
cylindrical, quartz cell of 2.4 mL capacity and 1 cm path
length, and then irradiated from a source (245 nm) at a dis-
tance of 13 cm for up to 3.5 h. This solution was measured
every half hour spectrophotometrically (to follow the time
needed for complete drug degradation) and by HPLC/MS
(to identify the intermediate compounds).3. Results and discussion
3.1. Method development and optimization of the
chromatographic conditions
Chromatographic conditions were optimized to obtain high
sensitivity, good peak shape and short retention time. The
separation and ionization of NIC was affected by the compo-
sition of mobile phase. Acetonitrile–water, acetonitrile–
acetate, hexane–ethanol and methanol–water in various
proportions were tested. In view of the response of NIC
retention times, 70% methanol was the best. The ionization
of NIC was increased by adding additive in the mobile
phase. Therefore, triethylamine (TEA) and acetic acid were
attempted to improve the response. When 30% TEAating HPLC method for the determination of nicardipine in capsules and spiked
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.044
6 S.M. Al-Ghannam, A.M. Al-Olayan(0.01 M) was added in the mobile phase, the peak shape of
NIC was improved. The response of NIC was increased by
adding acetic acid. Changing the pH over the range 3.5–5.0
was found to have no signiﬁcant effect either on the retention
factors of the drug and its degradation products or on the
UV intensity. Based on these experiments, pH 4.0 was used.
Finally, methanol/TEA (0.01 M) with acetic acid pH4 (70:30
v/v) was adopted as the mobile phase. Similarly the effect of
ﬂow rate was examined at 0.25, 0.5, 1.0 and 1.5 mL/min, the
ﬂow rate of 1.0 mL/min was used.
3.2. Purity assessment of nicardipine
Authenticity of the reference nicardipine could be assessed by
several analytical techniques such as IR, NMR, Mass spec-
trometry and chromatographic methods. The results obtained
were analyzed and matched with those of the with-submitted
analytical report obtained from the manufacturer. Fig. 1
showed the electro spray mass spectrum of nicardipine. The
peak of nicardipine is observed predominately as protonated
molecular species [M+ H+] (m/z 480). The probable struc-
tural changes in nicardipine molecule as result of degradation
can be easily elucidated by matching with the initial molecular
characteristics of the parent reference drug.
3.3. Stress studies
Stress testing of the drug substance can help to identify the
likely degradation products, which can in turn help to establish
the degradation pathways and the intrinsic stability of the mol-
ecule and validate the stability indicating powder of the analyt-
ical procedures used.
Stress degradation behavior. HPLC studies on NIC under
different stress conditions suggested that NIC is susceptible
to hydrolytic (acidic and alkaline), oxidative and photolytic
stress conditions. The optimized HPLC–MS method was used
to identify the degradation products of NIC. The HPLC–UV–
MS obtained for NIC under various stress conditions are given
in Fig. 2.
3.3.1. Acid hydrolysis
Nicardipine appears to be stable to acid degradation which is
in agreement with acid degradation of isradipine (Abdel
Ghany et al., 1998). It was observed that on heating at 60 C
in 1 M HCl, there was no degradation peak product eluted
in the chromatogram. Fig. 2A shows the chromatogram after
1 h of heating the reaction mixture at 60 C with HCl.
3.3.2. Alkaline hydrolysis
From the preliminary study conducted on the degradation of
nicardipine in 0.4 M NaOH at 60 C for 1 h, it is evident that
the drug underwent decomposition. The rate of alkaline hydro-
lysis was fast with signiﬁcant reduction in the peak area, and
new peaks of the degradation products were observed. The
drug was found to be highly susceptible to alkaline hydrolysis.
The reaction in 0.4 M NaOH at 60 C was so rapid that 50%
of the drug was degraded within 1 h, forming degradationPlease cite this article in press as: Al-Ghannam, S.M., Al-Olayan, A.M. Stability-indic
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nicardipine RT = 8.93 min. Fig. 2B. Study of the kinetic
parameters for the degradation of nicardipine involved mea-
suring the peak height of nicardipine only.
Table 1 and Fig. 3 show the increase in the value of the
reaction rate constant (K) and the decrease in the half-life time
(t1/2) upon increasing the concentration of sodium hydroxide.
The combination of effect of the concentration of sodium
hydroxide with the effect of time and temperature was studied.
Fig. 4 shows the effect of the combination of the three factors
for the concentration of 0.2 M of NaOH. Table 2 is a collec-
tion of the data representing the effect of increasing the con-
centration of NaOH at different temperature; the values of
the slopes; reaction rate constant; half-life time and activation
reaction are listed. As showed from the results the values of
activation energy were 55.27–65.67 J/mol K in agreement with
the corresponding values for the hydrolysis of esters (Conners
et al., 1979; Ibrahim et al., 2010).3.3.3. Oxidation
Fig. 2C shows the total ion chromatogram from the hydrogen
peroxide 5% degradation after 5 h of heating the reaction mix-
ture at 40 C. A single major component is observed at a reten-
tion time of 7.8 min. and comprises 100% of the original
sample. Table 3 listed the data of kinetic parameters for this
degradation at different temperature.3.3.4. Photolytic degradation
The most undesirable property of 1,4-DHPs from pharmaceu-
tical point of view is their high photochemical sensitivity which
can involve molecular changes leading to decrease of therapeu-
tic effect and even some toxic effects after administration
(Barand et al., 2006). In this part, the methanolic solution of
nicardipine (10 lg/mL) was exposed to the UV light at
245 nm to identify the photo degradation products for the
drug. As shown in Fig. 5, the exposure to UV light at wave-
length = 245 nm resulted in photo induced modiﬁcations of
the drug chromophore, as indicated by the signiﬁcant changes
of the UV spectral absorption of the solutions (irradiation time
0–210 min).
In particular a decrease of the absorption band at
k= 353 nm was observed in agreement with a previous study
on related 1,4-dihydropyridine derivatives (Albini and Fasani,
1998). This decrease of absorption suggests a signiﬁcant mod-
iﬁcation (aromatization) of the 1,4-dihydropyridine chromo-
phore (Alvarez-Lueje et al., 2003). Moreover, increased
absorption at k= 280 and 310 nm can be observed and is
attributed to formation of degradation products.
HPLC–UV chromatograms, acquired at 353 nm, of the
photo exposed solutions Fig. 2D showed the formation of four
photo degradation products at RT 4.40, 4.98, 6.06 and 7.13.
The high percentage of unchanged nicardipine showed that
this compound was much more stable compared with the other
1,4-dihydropyridine compounds for which no parent com-
pound was detectable after 2 h of light exposure (Barand
et al., 2006; Albini and Fasani, 1998; Alvarez-Lueje et al.,
2003; Pomponio et al., 2004).ating HPLC method for the determination of nicardipine in capsules and spiked
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.044
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3.4.1. Identiﬁcation of base degradation
The Chromatogram of NIC degradation showed two peaks in
addition to that of NIC. It is postulated that the decomposition
pathway as shown below:Upon heating NIC in alkaline medium, it undergoes the
following changes, the two ester groups attached to the dihy-
dropyridine ring are hydrolyzed, resulting in the formation
of CH3OH (P3) which is not detectable, and N-methyl-N-(2-
hydroxylethyl)benzylamine (P2).
At the same time, NIC undergoes photochemical decompo-
sition through auto-oxidation reduction resulting in reduction
of the nitro group to nitroso and oxidation of the dihydropyr-
idine ring (P1), as previously reported (Albini and Fasani,
1998).
Compound (P1), the acid fraction (present as sodium salt)
is highly polar, which have peak with high intensity more
than compound (P2) or nicardipine itself (Walash et al.,
2007). Fig. 6 shows the mass spectrum of degradation of
nicardipine with sodium hydroxide (0.4 M) at 60 C for 1 h,
it illustrate that compound (P1) has peak intensity of 100%
compared to the intensity of residual nicardipine which was
50%.
The LC/MS under the same conditions Fig. 2B shows two
peaks produced from the degradation which have same inten-
sity, therefore, it is proposed that two peaks appear to be iso-
mers since they have the same molecular weight 353 (P2)
appears in less intensity and at molecular weight 165.
3.4.2. Identiﬁcation of oxidative products
As mentioned before this oxidation produced one product.
Fig. 7 shows the mass spectra of nicardipine after degradation
by H2O2 5% at (a) t= 0 and (b) t= 5 h. It illustrates that thePlease cite this article in press as: Al-Ghannam, S.M., Al-Olayan, A.M. Stability-indic
human plasma. Identiﬁcation of degradation products using HPLC/MS. Arabian Jomajor compound appear at molecular weight 496. It proposed
that product result from the oxidation of dihydropyridine to
pyridine derivative in addition to the oxidation of the tertiary
amine to the N-oxide (Milcent and Chau, 2002). The increase
in molecular weight of 16 would tend to support this assign-
ment which is equal the molecular weight of hydroxyl[M + OH]. And the chromatogram is agreed with the
obtained mass spectrum where the intensity of the produced
compound is equal to 75% and the intensity of residual nicar-
dipine is equal to 50%. The proposed structure of oxidation
product of nicardipine with hydrogen peroxide is suggested
as follows:3.4.3. Identiﬁcation of photo degradation
In contrast to chemical degradation photo degradation shows
the formation of four different products Fig. 2B. The major
photo degradation product form through the conversion of
the dihydropyridine ring to a pyridine ring via loss of 2H+. This
product has been reported as themajor photo degradation prod-
uct from all of the dihydropyridine based calcium channel
blockers studied to date (Keaneth et al., 1984; Ibrahim et al.,
2010).ating HPLC method for the determination of nicardipine in capsules and spiked
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.044
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Figure 7 LC–MS spectrum of nicardipine solution (10 lg/mL) incubation with hydrogen peroxide for 5 h at 40 C, (a) 0 h and (b) 5 h,
MS conditions: 30 V for cone voltage, 3300 V for capillary voltage, 1.5 V for extraction voltage.
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Figure 8 LC–MS spectrum of nicardipine solution (10 lg/mL) in methanolic solution after different time of exposure to UV light: (a)
0 min, (b) 90 min and (c) 210 min, MS conditions: 30 V for cone voltage, 3300 V for capillary voltage, 1.5 V for extraction voltage.
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10 S.M. Al-Ghannam, A.M. Al-OlayanThe nicardipine mass spectra are shown in Fig. 8a along with
a scheme of fragmentation, represented of the fragmentation
pattern of all the main photoproducts. Fig. 8b shows reduction
of the peak atm/z= 466 resulting from the reduction of nitro to
nitrous group. Fig. 8c shows the proposed degradation prod-
ucts of nicardipine obtained after the exposure of a methanolic
solution (10 lg/mL) to UV (245 nm) light for 210 min.
3.5. Validation of the stability-indicating HPLC–MS method
The stability-indicating HPLC–MS assay method of NIC was
validated with respect to linearity, precision, accuracy and
speciﬁcity as per ICH guidelines (ICH-Harmonised Tripartite
Guideline, 2003).
3.5.1. Linearity
To establish linearity and range, a stock solution containing
1.0 mg/mL of NIC was diluted at different concentration
and response for the NIC was found to be linear in the concen-
tration range between 0.5 and 40 lg/mL. Linear regression
analysis of the data gave the following equation:
P ¼ 0:4046þ 0:6062C ðR2 ¼ 0:999Þ
where C is the concentration in lg/mL, P is the peak area ratio
and R is the correlation coefﬁcient. The result shows an excel-
lent correlation existed between the peak area ratio and con-
centration of the analyte.
3.5.2. Speciﬁcity and selectivity
The speciﬁcity of the method was established through study of
resolution factors of the drug peak from the nearest resolving
peak and also among all the other peaks (ICH-Harmonised
Tripartite Guideline, 2003). The presence/absence of peaks
due to excipients, impurities and degraded products was exam-
ined to study the interference from these substances in the
assay of the drug. A solution containing all the capsule excip-
ients omitting NIC was prepared and a blank plasma sample
was performed under the optimum chromatographic condi-
tions. No interfering peaks appeared in the chromatogram at
the retention time of the drug or its degradation product indi-
cating the speciﬁcity of the proposed method Fig. 9a.Figure 9 HPLC chromatograms of (a): plasma blank; (b) NIC
(10 lg/mL) in spiked human plasma.
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For repeatability, a solution of 10 lg/mL was injected three
times and the RSD of these three determinations was not more
than 1.9% and no change in retention time of the drug. Intra-
day and inter day dilutions of 5, 15, 30 lg/mL were injected
three times in the same day and in three consecutive days,
respectively. The overall RSD of both intraday and inter day
was not more than 1.2%.
3.5.4. Sensitivity
The limit of detection (LOD) and the limit of quantiﬁcation
(LOQ) of NIC were determined based on signal-to-noise ratio
of 3 and 10, respectively (United States Pharmacopoeia, 2007).
The baseline noise was measured in a blank experiment in the
region of retention time of NIC using chromatographic soft-
ware. It was found that, the LOD and LOQ values were
0.11 lg/mL and 0.036 lg/mL, respectively.
3.6. Applications
3.6.1. Dosage form analysis
The proposed method was successfully applied to the assay of
NIC in commercial capsules (Pelcard capsules, 50 mg). The
average percentage found of different concentrations of the
drug was based on the average of three replicate determina-
tions. The mean% recovery of NIC in the examined dosage
form was 100.11%. High percentage recovery values revealed
that the proposed method is accurate and could be adopted
for routine quality control.
3.6.2. Spiked human plasma analysis
Nicardipine is rapidly absorbed from the gastro intestinal tract
but is subjected to saturable ﬁrst-pass hepatic metabolism. Bio-
availability of about 35% has been reported following a 30 mg
dose at steady state. The terminal plasma half-life is about
8.6 h (Parﬁtt, 1999). The method could be successfully applied
to the determination of NIC in spiked human plasma Fig. 9b.
The plasma calibration curve was linear with the following
equation:
P ¼ 13:699þ 0:0713C ðR2 ¼ 0:9991Þ;
where P is the peak area ratio, C the concentration of the drug
in lg/mL and R is the correlation coefﬁcient. The accuracy of
the proposed method was assessed by investigating the recov-
ery of NIC at three concentration levels covering the speciﬁed
range using spectrophotometric detection. The mean% recov-
ery of NIC was 99.04%.
4. Conclusions
A rapid, precise and accurate HPLC method has been devel-
oped for the determination of NIC either alone or in the pres-
ence of its degradation products. The method is speciﬁc and
unaffected by the presence of degradants, indicating the meth-
od’s stability as a stability indicating assay of NIC, which is
suitable to identify all of the degradation products. The method
is also considered to be stability indicating assay for the deter-
mination of NIC in capsules without any interference from
excipients. The proposed procedure, by virtue of its high sensi-
tivity, could be applied to the analysis of NIC in spiked human
plasma with no need for extraction or pretreatment steps.ating HPLC method for the determination of nicardipine in capsules and spiked
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.11.044
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